Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia

The paper describes the outcomes from a clinical trial for Friedreich ataxia (the most common hereditary ataxia impacting walking, talking, heart and brain health). The trial did not show treatment efficacy.

Redenlab was the speech biomarker provider on the trial with Retrotope.

Click here to find out more.

Related Post

  • Posted on 25 January, 2024
    MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a groundbreaking study...
    • Posted on 25 January, 2024
      Exposing healthy adults to extended periods of wakefulness is known to induce changes in psychomotor functioning. The effect of fatigue...
      • Posted on 17 January, 2024
        While speech biomarkers of disease have attracted increased interest in recent years, a challenge is that features derived from signal...